Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept and Rosetta Genomics Collaborate to Evaluate microRNAs From Circulating Tumor Cells
SAN DIEGO and PRINCETON, N.J. and REHOVOT, Israel , Oct. 13, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA (cfDNA) and circulating tumor cells (CTCs), and Rosetta Genomics, Ltd.
View HTML
Toggle Summary Biocept Expands Collaboration With MD Anderson Cancer Center
Biocept's OncoCEE(TM) Platform Enhances Ovarian Cancer Research
View HTML
Toggle Summary Biocept to Present at the 13th Annual BIO Investor Forum
SAN DIEGO , Sept. 30, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis in circulating tumor cell (CTC) and circulating tumor DNA (ctDNA), today announced that Michael Nall , Biocept President and CEO, is scheduled to
View HTML
Toggle Summary Biocept Granted Patent in China for Its Microfluidic Channel Technology Used to Capture Circulating Tumor Cells
Patent Approval Further Strengthens Biocept's IP Position in Personalized Cancer Treatment in East-Asia
View HTML
Toggle Summary Biocept to Present at Upcoming Investor Conferences
SAN DIEGO, Sept. 4, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) biomarker analysis, today announced that Michael Nall, Biocept President and CEO, will be presenting a
View HTML
Toggle Summary Biocept Strengthens Its Circulating Tumor Cell IP Position in Europe
Key Microfluidic Channel Patent Granted to Biocept in Europe
View HTML
Toggle Summary Biocept Provides Second Quarter Operational Update
SAN DIEGO, Aug. 14, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) biomarker analysis, today provided a business update following the recent filing with the US Securities
View HTML
Toggle Summary Biocept Appoints Managed Care Expert to Lead Contract and Reimbursement Strategy
Quest Diagnostics and GE Healthcare Veteran Amy McNeal Brings Experience to Biocept Team
View HTML
Toggle Summary Biocept Expands Breast Cancer Offering
Blood-based OncoCEE-BR™ Platform now Includes Estrogen Receptor Testing SAN DIEGO, June 2, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA and circulating tumor cells (CTCs), today
View HTML
Toggle Summary Biocept Announces National Sales Force
Oncology Sales Specialists to Deploy Blood-Based Cancer Diagnostics Into Physician Practices and Pharmaceutical Development Markets
View HTML